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Abstract
Objective—Due to higher rates of human papillomavirus (HPV) infection and anal cancer
among gay and bisexual men, we aimed to characterize their willingness to get HPV vaccine and
identify correlates of vaccine acceptability.
Methods—We surveyed a national sample of men aged 18 to 59 who self-identified as either gay
(n = 236) or bisexual (n = 70) during January 2009. We analyzed data using multivariate logistic
regression.
Results—Most men had heard of HPV vaccine (73%, 224/306) and were willing to get it (74%,
225/306). HPV vaccine acceptability was higher among men who believed their doctor would
recommend getting the vaccine (OR = 12.87, 95% CI: 4.63–35.79) and those who were unsure
(OR = 3.15, 95% CI: 1.47–6.76), as compared to men who believed their doctor would not
recommend it. Acceptability was also higher among men who reported 5 or more lifetime sexual
partners (OR = 3.39, 95% CI: 1.34–8.55), perceived greater severity of HPV-related disease (OR =
1.92, 95% CI: 1.18–3.14), perceived higher levels of HPV vaccine effectiveness (OR = 1.97, 95%
CI: 1.27–3.06), or reported higher levels of anticipated regret if they did not get vaccinated and
later developed an HPV infection (OR = 2.39, 95% CI: 1.57–3.61).
Conclusions—HPV vaccine acceptability was high among gay and bisexual men. These
findings identify potentially important beliefs and attitudes for future communication efforts about
HPV and HPV vaccine among gay and bisexual men.
Human papillomavirus (HPV) infection is widespread among males, with recent prevalence
estimates ranging up to 73%.1-4 HPV-infected men face potentially severe health
consequences, although most infections resolve spontaneously. An estimated 63% of
oropharyngeal cancers, 93% of anal cancers, and 36% of penile cancers in the United States
(US) are attributable to infection with oncogenic HPV types (mainly types 16 and 18).5
Nononcogenic HPV types (types 6 and 11) cause anogenital warts.6
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HPV-related disease is of particular concern for gay and bisexual men. The estimated
prevalence of anal HPV infection among gay and bisexual men is about 60% among human
immunodeficiency virus (HIV)-negative individuals and even higher among HIV-positive
individuals, perhaps over 90%.7-9 Men who have sex with men (MSM) are also at greater
risk for anal cancer compared with the general population,10-12 with incidence rates
increasing over the last few decades.13
While a quadrivalent HPV vaccine is currently approved for use in females aged 9 to 26
years in the United States,14 studies have also shown the vaccine to be efficacious in males.
Early results have shown reductions in persistent HPV infection and genital warts among
vaccinated young men, including MSM.15-17 Although some men may not derive full
benefit due to previous exposure to HPV types in the vaccine, it may offer them important
protection against HPV vaccine types they have not been exposed to. As with females, HPV
vaccination likely offers the greatest benefit to males if administered before sexual
debut.18,19 Several countries have licensed HPV vaccine for use in males, though the United
States is not currently one of them.20 Austria is the only country to currently recommend
HPV vaccination for young males.20
In the event of approval of prophylactic HPV vaccine for use among males in the United
States, it is important to examine vaccine acceptability and potential correlates such as
knowledge and beliefs. Most studies that have addressed these topics in men have included
no or very few gay and bisexual men.21-26 The limited research conducted among gay and
bisexual men (primarily using convenience samples recruited at community events or sexual
health centers) found low levels of awareness and knowledge about HPV,27,28 as well as
moderate interest in receiving the vaccine.29
In this report, we aimed to characterize correlates of acceptability among a national sample
of gay and bisexual men. We examine modifiable beliefs as potential correlates of HPV
vaccine acceptability among this high-risk population, focusing on constructs from health




We interviewed men aged 18 to 59 years who were members of an existing national panel of
US households maintained by Knowledge Networks (Menlo Park, CA) in January 2009,
oversampling men who self-identified as gay or bisexual for our study. Knowledge
Networks identified prospective panel members using list-assisted, random-digit dialing.
Households containing one or more panel members receive free internet access in exchange
for panel members completing multiple internet-based surveys each month. Panel members
in households with existing computer and internet access accumulate points as they
complete surveys, which can then be redeemed for small cash payments at regular intervals.
Of 874 men invited to participate, 609 (70%) completed our cross-sectional, online
survey.33 We report data collected from men who self-identified as either gay (n = 236) or
bisexual (n = 70), excluding 12 men who indicated that they were not heterosexual but did
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not label their sexual orientation as either gay or bisexual. The Institutional Review Board at
the University of North Carolina approved the study.
Measures
The University of North Carolina Men’s Health Survey is available online at http://
www.unc.edu/~ntbrewer/hpv.htm. We developed survey items based on our previous HPV
vaccine research involving females, parents, and healthcare providers.31,32,34 We
cognitively tested the survey with 28 gay and bisexual men and further refined it with 8
additional men (including 5 gay and bisexual men) before the study.
The survey measured HPV vaccine acceptability using 5 items assessing how willing a
participant would be to get HPV vaccine if it were approved for use in males (α = 0.97).
Response options were “definitely not willing,” “probably not willing,” “not sure,”
“probably willing,” and “definitely willing.” We classified each participant as either “willing
to get HPV vaccine” (responded probably or definitely willing to 3 or more items) or “not
willing to get HPV vaccine.”
The survey measured HPV awareness by asking participants if they had ever heard of HPV
before the survey. We calculated an HPV knowledge score by summing correct responses to
9 individual items (each correct answer was 1 point) asked only of men who had heard of
HPV (Fig. 1). For analyses, we classified participants as “unaware of HPV” if they had
never heard of HPV, aware of HPV with “low knowledge” if they had heard of HPV but
answered 4 or less knowledge items correctly, or aware of HPV with “high knowledge” if
they had heard of HPV and answered at least 5 knowledge items correctly.
After providing informative statements about HPV and HPV vaccine, the survey assessed
awareness of the vaccine by asking participants if they had ever heard of it before the
survey. The statements informed participants that HPV is a common sexually transmitted
infection (STI), about diseases associated with HPV, and that a vaccine exists to protect girls
and young women against cervical disease. Participants indicated whether they had ever
received any doses of HPV vaccine, attempted to get HPV vaccine but were unsuccessful,
talked to a doctor about getting HPV vaccine for themselves, whether any family members
or friends had received HPV vaccine, and where they would most likely go to get HPV
vaccine (if it were approved for males). The survey also assessed whether participants
thought their healthcare providers would recommend they get the vaccine if it were
approved for males.
The survey used multi-item scales to measure perceived knowledge of HPV-related disease
(3 items, possible range = 1–4, α = 0.74), level of concern about getting HPV-related
disease (3 items, possible range = 1–4, α = 0.53), perceived severity of HPV-related disease
(3 items, possible range = 1–4, α = 0.69), and anticipated regret of not getting HPV vaccine
and later developing genital warts or an HPV infection that could lead to cancer (2 items,
possible range = 1–4, α = 0.88). HPV-related diseases addressed in the perceived
knowledge, concern, and perceived severity scales were genital warts, anal cancer, and oral
cancer. Perceived knowledge response options ranged from “nothing at all” to “quite a lot,”
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while concern, perceived severity, and anticipated regret items had response options ranging
from “not at all” to “quite a lot.”
The survey measured perceived potential barriers to obtaining HPV vaccine with a 4-item
scale (possible range = 1–5, α = 0.65) that addressed adverse effects of HPV vaccination,
cost of HPV vaccine, and difficulty in finding a health care provider with the vaccine
available for males (if approved for use). For each perceived potential barrier, response
options ranged from “not at all” to “extremely.” The survey also assessed perceived
effectiveness of the vaccine against HPV-related disease (4 items, possible range = 1–5, α =
0.94) and perceived likelihood of getting HPV-related disease (4 items, possible range = 1–
5, α = 0.85) using multi-item scales. HPV-related diseases addressed in these scales were
genital warts, anal cancer, oral cancer, and penile cancer. Response options ranged from “no
protection” to “complete protection” for effectiveness items and “no chance” to “certain I
will get (HPV-related disease)” for likelihood items.
Participants provided information on demographic variables and health behaviors (Table 1).
We defined “urban” as living in a metropolitan statistical area and “rural” as living outside
of an metropolitan statistical area.35 The survey also collected information on reported
history of STIs and cancer (oral, anal, or penile) or lesions (anal or penile).
Data Analysis
We used logistic regression models to examine bivariate correlates of HPV vaccine
acceptability. Statistically significant bivariate predictors (P < 0.05) were entered into a
multivariate logistic regression model. We analyzed unweighted data using SPSS version
16.0 (SPSS Inc., Chicago, IL). All statistical tests were 2-tailed, using a critical α of 0.05.
RESULTS
Participant Characteristics
Most participants were non-Hispanic white (81%), less than 50 years old (60%), reported an
income of at least $60,000 (60%), employed (80%), had health insurance (86%), and lived
in an urban area (93%) (Table 1). A majority of participants were nonsmokers (72%) and
had either not received or were unsure if they had received one or more doses of hepatitis B
vaccine (56%). Most men reported that they had not initiated sex before age 16 (65%) and a
history of 5 or more sexual partners during their lifetime (89%) (median number of reported
lifetime sexual partners = 25). Seventeen percent of men reported a history of HIV infection,
32% reported a history of other STIs, and 2% indicated a history of cancer (oral, anal, or
penile) or lesions (anal or penile).
HPV and HPV Vaccine Awareness and Knowledge
Most men (79%) reported hearing of HPV before the survey, but knowledge levels about
HPV tended to be low among those who had. Men, on average, answered 49% of the 9
knowledge questions correctly (mean = 4.39, median = 4 of 9 items correct). Most
participants knew that HPV is an STI (74%) and that it is a common infection (74%) (Fig.
1). Only 58% thought HPV causes health problems for males, with even fewer knowing
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HPV can cause genital warts (46%) and cancer (anal cancer = 32%, penile cancer = 28%,
oral cancer = 25%). Knowledge items with the highest percentage of incorrect responses
concerned whether HPV causes genital herpes (33%), oral cancer (25%), or penile cancer
(24%). In terms of HPV vaccine, most men (73%) reported hearing of it before the survey.
Beliefs About HPV and HPV Vaccine
Men expressed relatively low levels of perceived knowledge about HPV-related disease
(mean = 1.80, SD = 0.63) and concern about getting HPV-related disease (mean = 1.55, SD
= 0.54), as well as moderate levels of perceived likelihood of getting HPV-related disease
(mean = 2.19, SD = 0.55). Participants generally perceived HPV-related disease to be severe
(mean = 3.32, SD = 0.66). Participants also perceived HPV vaccine to be moderately
effective in protecting against HPV-related disease (mean = 3.03, SD = 0.82), some barriers
to getting HPV vaccine if it were available for males (mean = 2.67, SD = 0.85), and high
levels of anticipated regret if they did not get vaccinated and later got an HPV infection
(mean = 3.39, SD = 0.84). While about one-third of men (34%) thought their doctor would
recommend they get HPV vaccine if it were approved for males, almost half were unsure
(48%).
HPV Vaccine Uptake and Acceptability
No men had received HPV vaccine, 3% reported talking to a doctor previously about getting
the vaccine for themselves, and 8% reported a family member or friend had been vaccinated.
Three men reported trying to get HPV vaccine but were unsuccessful in doing so, indicating
that affordability of the vaccine (n = 2) and the doctor not giving HPV vaccine to males (n =
1) prevented them from getting it. If approved for males, men indicated they would most
likely go to a primary healthcare provider’s office (78%) or gay health center (8%) to get
HPV vaccine.
Approximately 74% (225/306) of men were willing to receive HPV vaccine. Multiple
variables were associated with acceptability of HPV vaccine in bivariate analyses (Tables 1
and 2). Men who either thought or were unsure if their doctor would recommend HPV
vaccine, had received one or more doses of hepatitis B vaccine, or reported 5 or more
lifetime sexual partners were more willing to get HPV vaccine (all P < 0.05). Furthermore,
men willing to get vaccinated reported higher levels of concern about getting HPV-related
disease, perceived severity of HPV-related disease, perceived likelihood of getting HPV-
related disease, perceived effectiveness of HPV vaccine, and anticipated regret if they did
not get vaccinated and later became infected with HPV (all P < 0.05).
In multivariate analysis (Table 3), acceptability was higher among men if they either thought
(OR = 12.87, 95% CI: 4.63–35.79) or were unsure (OR = 3.15, 95% CI: 1.47–6.76) if their
doctor would recommend they get HPV vaccine compared with those who thought their
doctor would not recommend the vaccine, if made available for males. Acceptability was
also higher among those who had 5 or more lifetime sexual partners (OR = 3.39, 95% CI:
1.34–8.55), perceived HPV-related disease to be more severe (OR = 1.92, 95% CI: 1.18–
3.14), perceived HPV vaccine to be more effective (OR = 1.97, 95% CI: 1.27–3.06), or
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reported greater anticipated regret if they did not get vaccinated and an HPV infection later
developed (OR = 2.39, 95% CI: 1.57–3.61).
DISCUSSION
If approved for use in males, HPV vaccine may offer great benefits to gay and bisexual men
due to their high rates of HPV infection7-9 and HPV-associated anal cancer.12 We currently
know little about the acceptability of the vaccine among gay and bisexual men. In this
national sample of gay and bisexual men, most were willing to get HPV vaccine.
Furthermore, many of the identified correlates of HPV vaccine acceptability are modifiable
and offer potential targets for future research addressing HPV and HPV vaccine in gay and
bisexual males.
About three-fourth of participants were willing to get vaccinated against HPV. This level of
HPV vaccine acceptability is higher than a past study conducted among MSM.29
Acceptability of HPV vaccine was higher among men who perceived HPV-related disease to
be more severe, perceived HPV vaccine to be more effective, or thought or were unsure if
their doctor would recommend they get HPV vaccine (although effect estimates for doctor’s
recommendation were imprecise due to small cell counts and should be interpreted
accordingly). These findings are similar to those of HPV vaccine acceptability research
conducted among females and parents of adolescent girls (before federal approval of the
vaccine for females).30 While males have also reported increased willingness to get HPV
vaccine if their doctor recommended it,22 neither perceived severity of HPV-related disease
nor perceived HPV vaccine effectiveness were multivariate correlates of HPV vaccine
acceptability in a previous study among heterosexual males.23 Acceptability was also higher
among men in our study who reported greater anticipated regret if they did not get
vaccinated and an HPV infection later developed. While we identified anticipated regret as a
key predictor of HPV vaccine uptake among adolescent females,36 it has not been
previously examined as a correlate of HPV vaccine acceptability among males, to our
knowledge. These findings identify potentially important beliefs and attitudes for future
communication efforts about HPV and HPV vaccine among gay and bisexual men.
Although most participants were willing to get vaccinated, knowledge of potential health
consequences of HPV infection was low. Furthermore, over 20% of men had not even heard
of HPV before the survey. These findings are in line with previous reports of low HPV
knowledge among gay and bisexual men.27,28 Given the high levels of anal HPV infection
among gay and bisexual men,7-9 these results are especially concerning. Future efforts need
to ensure that gay and bisexual men are aware of not only HPV and how it is transmitted,
but also diseases associated with HPV infection and how infected men can reduce their risk
of developing HPV-related cancers. Such efforts may increase informed decision-making
about HPV vaccine (and potentially vaccine acceptability) among this high-risk population.
A few important issues will need to be considered before targeting gay and bisexual men for
vaccination should the vaccine become available for males. HPV vaccination likely offers
the greatest benefit if administered before sexual debut.18,19 However, most MSM report
engaging in their first same-sex experience before disclosing their sexual orientation to
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others.37 Consequently, men identifying as gay and bisexual who have not yet had sexual
intercourse (the ideal target population) may be a difficult population to identify. One
alternative public health strategy may be to target all males at an early age before sexual
intercourse, similar to the current strategy for vaccinating females.
Many sexually active gay and bisexual men will likely seek HPV vaccine if it becomes
available for males, including those with previous HPV infections. In our study, as well as
others among primarily heterosexual men,22,25 acceptability of HPV vaccine was higher
among men with more lifetime sexual partners, a marker of risk for HPV infection.
Nonetheless, most MSM are not currently infected in the anal canal with either HPV 16 or
18 and are unlikely to be infected with all 4 HPV types the quadrivalent vaccine protects
against.8,9 If additional research determines that vaccinating sexually active men offers
health benefits, these gay and bisexual men with previous sexual activity may become an
important population for ensuring HPV vaccination.
The strengths of our study include the use of a national sample, a high participation rate, and
examining a wide range of possible correlates of willingness to get HPV vaccine. We also
focused on gay and bisexual men, who are at high risk for HPV-related disease. Limitations
include the study occurring before HPV vaccine licensure for males in the United States and
the inclusion of men outside the age range of those in clinical trials involving HPV vaccine
safety and efficacy in males.15-17 Age, however, was not associated with vaccine
acceptability. While we used members of an online survey panel, the panel has been shown
to closely match the US population on many demographic features.38,39 The main outcome,
willingness to get HPV vaccine, may overstate behavior that we would observe if HPV
vaccine is approved for use in males since intent does not always translate into health
behavior.40,41 This issue may be especially relevant in the case of HPV vaccination in the
United States since the vaccine is not currently provided free of charge within schools, as in
other countries.42
The findings of the current study suggest that a substantial proportion of gay and bisexual
men are willing to get HPV vaccine. Modifiable beliefs, including perceived HPV vaccine
effectiveness and anticipated regret, may be important to future communication efforts about
HPV and HPV vaccine among gay and bisexual men. While future research involving males
in the likely targeted age range for HPV vaccine is warranted, our results offer early insight
into both HPV vaccine acceptability among gay and bisexual men and correlates of this
acceptability.
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Responses to HPV knowledge items among gay and bisexual men who had heard of HPV
before survey (n = 243). Correct answer is yes, except for items with superscript (*).
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TABLE 1
Categorical Correlates of HPV Vaccine Acceptability Among Gay and Bisexual Men (n = 306)
No. Willing to Get HPV Vaccine/




  Sexual self-identity
    Bisexual 48/70 (69) ref.
    Gay 177/236 (75) 1.38 (0.77-2.47)
  Age (yr)
    18-39 41/59 (69) ref.
    40-49 96/124 (77) 1.51 (0.75-3.02)
    50-59 88/123 (71) 1.10(0.56-2.18)
  Race/ethnicity
    White, non-Hispanic 180/247 (73) ref.
    Other race/ethnicity 45/59 (76) 1.20 (0.62-2.32)
  Marital status
    Divorced, widowed, separated, never married 117/160 (73) ref.
    Living with partner or married 108/146 (74) 1.05 (0.63-1.74)
  Education level
    No college degree 94/136 (69) ref.
    College degree 131/170 (77) 1.50 (0.90-2.50)
  Household income
    <$60,000 87/122 (71) ref.
    ε$60,000 138/184 (75) 1.21 (0.72-2.02)
  Employment status
    Not currently employed 40/60 (67) ref.
    Currently employed 185/246 (75) 1.52 (0.82-2.79)
  Health insurance status
    No 30/44 (68) ref.
    Yes 195/262 (74) 1.36 (0.68-2.71)
  Urbanicity
    Rural 16/20 (80) ref.
    Urban 209/286 (73) 0.68 (0.22-2.09)
HPV and HPV vaccine
  Awareness/knowledge about HPV
    Never heard of HPV before survey 43/63 (68) 0.70 (0.36-1.38)
    Heard of HPV, at or below median knowledge score 93/125 (74) 0.95(0.53-1.69)
    Heard of HPV, above median knowledge score 89/118 (75) ref.
  Heard of HPV vaccine before survey
    No 60/82 (73) ref.
    Yes 165/224 (74) 1.03 (0.58-1.82)
  Family member or friend has gotten HPV vaccine
    No 208/283 (73) ref.
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No. Willing to Get HPV Vaccine/
Total No. in Category (n %)
Bivariate
OR (95% CI)
    Yes 17/23 (74) 1.02 (0.39-2.69)
  Think doctor would recommend HPV vaccine
    No 25/56 (45) ref.
    Do not know 105/147 (71) 3.10 (1.64-5.86)*
    Yes 95/103 (92) 14.73 (6.03-35.98)*
Health and health behaviors
  Smoking status
    Nonsmoker 157/219 (72) ref.
    Smoker 68/87 (78) 1.41 (0.79-2.54)
  Hepatitis B vaccination history
    No doses received/do not know 118/171 (69) ref.
    At least one dose received 107/135 (79) 1.72 (1.01-2.91)†
  Age at first sexual intercourse (yr)
    <16 83/108 (77) 1.31 (0.76-2.26)
    ≥16 142/198 (72) ref.
  No. lifetime sexual partners
    <5 18/35 (51) ref.
    ≥5 207/271 (76) 3.06 (1.49-6.27)*
  HIV status
    Negative 185/255 (73) ref.
    Positive 40/51 (78) 1.38 (0.67-2.83)
  Other prior STI diagnosis
    No 152/209 (73) ref.
    Yes 73/97 (75) 1.14 (0.66-1.98)
  Prior diagnosis of cancer (oral, anal, penile) or lesions
(anal, penile)
    No 222/301 (74) ref.
    Yes 3/5 (60) 0.53 (0.09-3.25)
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TABLE 2
Continuous Correlates of HPV Vaccine Acceptability Among Gay And Bisexual Men (n = 306)
Mean (SD)
Bivariate
OR (95% CI)Not Willing (n = 81) Willing (n = 225)
Perceived knowledge of HPV-related disease 1.72 (0.63) 1.83 (0.62) 1.37 (0.89-2.10)
Concern about getting HPV-related disease 1.40 (0.51) 1.60 (0.54) 2.21 (1.25-3.91)*
Perceived severity of HPV-related disease 3.09 (0.76) 3.41 (0.60) 1.98 (1.36-2.88)*
Perceived likelihood of getting HPV-related disease 2.03 (0.63) 2.25 (0.51) 2.22 (1.32-3.72)*
Perceived barriers to getting HPV vaccine 2.73 (0.88) 2.64 (0.83) 0.88 (0.65-1.19)
Perceived effectiveness of HPV vaccine 2.58 (0.87) 3.19(0.74) 2.76 (1.91-3.97)*
Anticipated regret if chose not to get vaccinated and later
developed HPV infection
2.81 (1.05) 3.60 (0.62) 3.02(2.17-4.20)*
HPV indicates human papillomavirus; OR, odds ratio; CI, confidence interval.
*
P < 0.01.
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TABLE 3
Multivariate Correlates of HPV Vaccine Acceptability Among Gay and Bisexual Men (n = 306)
Adjusted OR (95% CI)
Think doctor would
recommend HPV vaccine
  No ref.
  Do not know 3.15(1.47-6.76)*
  Yes 12.87 (4.63-35.79)*
Hepatitis B vaccination history
  No doses received/do not know ref.
  At least 1 dose received 1.37 (0.70-2.69)
No. Lifetime sexual partners
  <5 ref.
  ≥5 3.39 (1.34-8.55)*
Concern about getting HPV-related disease 0.96 (0.48-1.90)
Perceived severity of HPV-related disease 1.92(1.18-3.14)*
Perceived likelihood of getting HPV-related disease 1.84 (0.92-3.70)
Perceived effectiveness of HPV vaccine 1.97 (1.27-3.06)*
Anticipated regret if chose not to get vaccinated and later developed HPV infection 2.39 (1.57-3.61)*
Multivariate model consisted of all variables included in table.
HPV indicates human papillomavirus; OR, odds ratio; CI, confidence interval; ref., referent group.
*
P < 0.01.
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